Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31105467 | 1.00 | KDM4E (0.31) | KDM4EPOLBMAPT | |
| SCHEMBL31674053 | 1.00 | KDM4E (0.31) | KDM4EPOLBMAPT | |
| Hydrochloric Acid SCHEMBL31674319 | 0.98 | KDM4E (0.31) | KDM4EPOLBMAPT | |
| SCHEMBL15572544 | 0.79 | FFAR3 (0.31) | — | |
| SCHEMBL15507730 | 0.79 | FFAR3 (0.31) | — | |
| SCHEMBL16585975 | 0.78 | — | — | |
| SCHEMBL31105209 | 0.77 | PKM (0.34) | — | |
| SCHEMBL11295244 | 0.76 | — | — | |
| SCHEMBL11294916 | 0.76 | — | — | |
| SCHEMBL11954281 | 0.76 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4731626-A1 | PI3K INHIBITORS AND USE THEREOF | Regor Pharmaceuticals, Inc. (US) | 2026-04-29 | — | — | EP | disclosed |
| WO-2024260464-A1 | PI3K INHIBITORS AND USE THEREOF | REGOR PHARMACEUTICALS, INC. (US) | 2024-12-26 | — | — | WO | disclosed |
| EP-2470546-B1 | HEXAHYDROOXAZINOPTERIDINE COMPOUNDS FOR USE AS MTOR INHIBITORS | TAKEDA PHARMACEUTICAL (JP) | 2013-07-24 | — | — | EP | disclosed |
| US-8268819-B2 | Hexahydrooxazinopterine compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-09-18 | — | — | US | disclosed |
| US-20120178924-A1 | HEXAHYDROOXAZINOPTERINE COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-07-12 | — | — | US | disclosed |
| EP-2470546-A1 | HEXAHYDROOXAZINOPTERINE COMPOUNDS FOR USE AS mTOR INHIBITORS | Takeda Pharmaceutical Company Limited (JP) | 2012-07-04 | — | — | EP | disclosed |
| US-8163755-B2 | Hexahydrooxazinopterine compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-04-24 | — | — | US | disclosed |
| WO-2011025889-A1 | HEXAHYDROOXAZINOPTERINE COMPOUNDS FOR USE AS mTOR INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-03-03 | — | — | WO | disclosed |
| US-20110053921-A1 | HEXAHYDROOXAZINOPTERINE COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120178924-A1 | HEXAHYDROOXAZINOPTERINE COMPOUNDS | HPRT1, HCCS, NUDT1 | KDM4E 4488/4885POLB 926/4885MAPT 4444/4885 |
| US-20110053921-A1 | HEXAHYDROOXAZINOPTERINE COMPOUNDS | MTOR, RICTOR, EIF4EBP1 | KDM4E 1340/4885POLB 2418/4885MAPT 3211/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.